Lau G.Yu M.-L.Wong G.Thompson A.Ghazinian H.Hou J.-L.Piratvisuth T.Jia J.-D.Mizokami M.Cheng G.Chen G.-F.Liu Z.-W.Baatarkhuu O.ANN-LII CHENGNg W.L.Lau P.Mok T.Chang J.-M.Hamid S.Dokmeci A.K.Gani R.A.Payawal D.A.Chow P.Park J.-W.Strasser S.I.Mohamed R.Win K.M.Tawesak T.Sarin S.K.Omata M.2022-02-212022-02-2120211936-0533https://www.scopus.com/inward/record.uri?eid=2-s2.0-85113351403&doi=10.1007%2fs12072-021-10239-x&partnerID=40&md5=db1fc9b2b11144a10805cb46b8562fcahttps://scholars.lib.ntu.edu.tw/handle/123456789/594871Background & Aim: Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clinicians in all disciplines involved in the use of immunosuppressive therapy to effectively prevent and manage hepatitis B reactivation. Methods: All publications related to hepatitis B reactivation with the use of immunosuppressive therapy since 1975 were reviewed. Advice from key opinion leaders in member countries/administrative regions of Asian-Pacific Association for the study of the liver was collected and synchronized. Immunosuppressive therapy was risk-stratified according to its reported rate of hepatitis B reactivation. Recommendations: We recommend the necessity to screen all patients for hepatitis B prior to the initiation of immunosuppressive therapy and to administer pre-emptive nucleos(t)ide analogues to those patients with a substantial risk of hepatitis and acute-on-chronic liver failure due to hepatitis B reactivation. ? 2021, Asian Pacific Association for the Study of the Liver.APASL; Guideline; Hepatitis B reactivation; Immunosuppressive therapy[SDGs]SDG3biological product; hepatitis B core antibody; hepatitis B surface antigen; monoclonal antibody; nucleoside analog; antivirus agent; hepatitis B surface antigen; immunosuppressive agent; Article; chronic liver failure; clinical assessment; coinfection; hepatitis B; Hepatitis B virus; hepatologist; human; immunopathogenesis; immunosuppressive treatment; infection risk; liver function test; morbidity; mortality rate; patient care; practice guideline; risk assessment; risk factor; virus reactivation; chronic hepatitis B; hepatitis B; virus activation; Antiviral Agents; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Virus Activationjournal article10.1007/s12072-021-10239-x344278602-s2.0-85113351403